Listing of Claims:

Please note the claims remain as follows, noting also that this listing of claims technically replaces all prior versions, and prior listings of claims in the application:

1. (Previously Presented): A compound of formula (I)

G_1-L-G_2

(I)

or a pharmaceutically acceptable salt thereof, wherein:

-G_1 is a radical (II)



(II)

wherein -R' is an electron pair or a (C_1-C_3)-alkyl radical; with the condition that

(i) when -R' is an electron pair, a is a N=C double bond and the fused ring

is the biradical



thus radical (II) is (IIa'), and



(IIa')

(ii) when -R' is a (C_1-C_3)-alkyl radical, a is a N-C single bond and the fused ring is the triradical



thus radical (II) is (IIa");



(IIa")

wherein -R_1 to -R_{12} represent radicals, same or different, selected from the group consisting of H, (C_1-C_4)-alkyl, (C_1-C_4)-alkoxy, (C_1-C_4)-alkylamino, phenyl, F, Cl, Br, amino, hydroxy, and nitro;

and wherein -B- is a biradical selected from the group consisting of -CONH- , -NR_{13}- , -O- ,-$(CH_2)_n$NH- , -$(CH_2)_n$O- , and -CO[NHCHR"CO]$_m$O- ; wherein -R_{13} is selected from the group consisting of H, (C_1-C_4)-alkyl, (C_1-C_4)-alkoxy and (C_1-C_4)-alkylamino; -R" are side chains radicals, same or different, corresponding to natural aminoacids; n is an integer from 1 to 3 and m is an integer from 1 to 3;

-L- is a single covalent bond or a covalent linking biradical selected from the following ones;

$$-(CH_2)_rNR'''(CH_2)_s-$$

$$-(CH_2)_rNR'''(CH_2)_sNR''''(CH_2)_t-$$

wherein -R''' and -R'''' are radicals, same or different, selected from the group consisting of H and (C_1-C_3)-alkyl; r is an integer from 1 to 3; s is an integer from 1 to 3; t is an integer from 1 to 3; and

-G_2 is a radical selected from a radical of formula (II), the N-radical of 1,8-naphthalimide, the C4-radical of 2-phenylquinoline, and the C9-radical of acridine.

2. (Previously Presented): The compound according to claim 1, wherein (II) is the radical (IIa').



(IIa')

3. (Original): The compound according to claim 2, wherein -B- is selected from the group consisting of -CONH- and $-NR_{13}-$.

4. (Original): The compound according to claim 2, wherein -B- is $-CO[NHCHR''CO]_mO-$.

5. (Original): The compound according to claim 4, wherein m = 2, the leftward -R'' is a glicine side chain, and the rightward -R'' is an arginine side chain.

6. (Previously Presented): The compound according to claim 2, wherein -L- is a single covalent bond.

7. (Previously Presented): The compound according to claim 2, wherein -L- is a covalent linking biradical selected from the following ones.

$-(CH_2)_rNR'''(CH_2)_s-$

$-(CH_2)_rNR'''(CH_2)_sNR''''(CH_2)_t-$

8. (Previously Presented): The compound according to claim 7, wherein -L- is the biradical
$-(CH_2)_rNR'''(CH_2)_s-$, -R''' is methyl, and both r and s are 3.

9. (Previously Presented): The compound according to claim 7, wherein -L- is the covalent linking biradical $-(CH_2)_rNR'''(CH_2)_sNR''''(CH_2)_t-$, both -R''' and -R'''' are methyl; both r and t are 2, and s is 2 or 3.

10. (Previously Presented): The compound according to claim 1, wherein (II) is the radical (IIa'').



(IIa")

11. (Previously Presented): The compound according to claim 10, wherein -B- is selected from the group consisiting of -CONH- and -NR_{13}- .

12. (Previously Presented): The compound according to claim 10, wherein -B- is -$CO[NHCHR"CO]_mO$- .

13. (Previously Presented): The compound according to claim 12, wherein m = 2, the leftward -R" is a glicine side chain, and the rightward -R" is the arginine side chain.

14. (Previously Presented): The compound according to claim 10, wherein -R' is methyl.

15. (Previously Presented): The compound according to claim 14, wherein -L- is a single covalent bond.

16. (Previously Presented): The compound according to claim 14, wherein -L- is a biradical selected from the following ones.

$-(CH_2)_rNR'"(CH_2)_s-$

$-(CH_2)_rNR'"(CH_2)_sNR""(CH_2)_t-$

17. (Previously Presented): The compound according to claim 16, wherein -L- is the biradical $-(CH_2)_rNR'"(CH_2)_s-$, R'" is methyl, and both r and s are 3.

18. (Previously Presented): The compound according to claim 16, wherein -L- is the biradical $-(CH_2)_rNR'"(CH_2)_sNR""(CH_2)_t-$, both -R'" and -R"" are methyl; both r and t are 2, and s is an integer from 2 to 3.

19. (Previously Presented): The compound according to claim 1, which is selected from the group consisting of:

N-[3-[[3-[(9-acridinecarbonyl)amino]propyl]methylamino]propyl]-10H-indolo[3,2-b]quinoline-11-carboxamide (Ia);

N,N'-(4-methyl-4-azaheptamethylene)-di-(10H-indolo[3,2-b]quinoline-11,11'-carboxamide) (Ib);

N-[3-[3-[[2-(1,3-dioxo-(2,3-dihydro)-1H-benzo[de]isoquinolinyl]propyl] methylamino]propyl]-10H-indolo[3,2-b]quinoline-11-carboxamide (Ic);

N-[3-[[3-[(2-phenyl-4-quinolinecarbonyl)amino]propyl]methylamino]propyl]- 10H-indolo[3,2-b]quinoline-11-carboxamide (Id);

N,N'-(3,7-dimethyl-3,7-diazanonamethylene)-di-(10H-indolo[3,2-b]quinoline-11,11'-carboxamide) (Ie);

N-[(9-acridinecarbonyl)-3,7,10-triaza-3,7-dimethyldecyl]-10H-indolo[3,2-b]quinoline-11-carboxamide (If);

N,N'-(3,6-dimethyl-3,6-diazaoctamethylene)-di-(10H-indolo[3,2-b]quinoline-11-11'-carboxamide (Ig);

N-[(9-acridinecarbonyl)-3,6-dimethyl-3,6-diazaoctamethylene]-10H-indolo[3,2-b]quinoline-11-carboxamide (Ih);

N-[[1,3-dioxo-(2,3-dihydro)-1H-benzo[de]isoquinolyl]-3,6-dimethyl-3,6-diazaoctamethylene]-10H-indolo[3,2-b]quinoline-11-carboxamide (Ii);

N-[[1,3-dioxo-(2,3-dihydro)-1H-benzo[de]isoquinolyl]-3,7,10-triaza-3,7-dimethyldecyl]-10H-indolo[3,2-b]quinoline-11-carboxamide (Ij);

N,N'-(4-methyl-4-azaheptamethylene)-di-(5-methyl-5H-indolo[3,2-b]quinoline-11,11'-carboxamide) (Im);

N,N'-(4-methyl-4-azaheptamethylen)-di-(5-methyl-5H-indolo[3,2-b]quinoline-11,11'-amine (Iq);

N,N'-(3,7-dimethyl-3,7-diazanonamethylene)-di-(5-methyl-5H-indolo[3,2-b]quinoline-11,11'-carboxamide) (Iy);

N,N'-(3,6-dimethyl-3,6-diazaoctamethylene)-di-(5-methyl-5H-indolo[3,2-b]quinoline-11,11'-carboxamide) (Iz);

(3,7-diazanonamethylene)-di-(10H-indolo[3,2-b]quinoline-11,11'-carboxamide (Iaa);

N,N'-(3,7-dimethyl-3,7-diazanonamethylene)-di-(5-methyl-5H-indolo[3,2-b]quinoline-11,11'-amine (Iab); and

N,N'-(3,6-dimethyl-3,6-diazaoctamethylene)-di-(5-methyl-5H-indolo[3,2-b]quinoline-11,11'-amine (Iac).

20. (Previously Presented): A method for the treatment of cancer which comprises administering to a subject a therapeutically effective amount of a compound of formula (I)

G_1-L-G_2

(I)

or a pharmaceutically acceptable salt thereof, wherein:

-G_1 is a radical (II)



(II)

wherein -R' is an electron pair or a (C_1-C_3)-alkyl radical; with the condition that

(i) when -R' is an electron pair, a is a N=C double bond and the fused ring

is the biradical



thus radical (II) is (IIa'), and



(IIa')

(ii) when -R' is a (C_1-C_3)-alkyl radical, a is a N-C single bond and the fused ring

is the triradical



thus radical (II) is (IIa");



(IIa")

wherein -R_1 to -R_{12} represent radicals, same or different, selected from the group consisting of H, (C_1-C_4)-alkyl, (C_1-C_4)-alkoxy, (C_1-C_4)-alkylamino, phenyl, F, Cl, Br, amino, hydroxy, and nitro;

and wherein -B- is a biradical selected from the group consisting of -CONH- , -NR_{13}- , -O- ,-$(CH_2)_n$NH- , -$(CH_2)_n$O- , and -CO[NHCHR"CO]$_m$O- ; wherein -R_{13} is selected from the group consisting of H, (C_1-C_4)-alkyl, (C_1-C_4)-alkoxy and (C_1-C_4)-alkylamino; -R" are side chains radicals, same or different, corresponding to natural aminoacids; n is an integer from 1 to 3 and m is an integer from 1 to 3;

-L- is a single covalent bond or a covalent linking biradical selected from the following ones;

-$(CH_2)_r$NR'"$(CH_2)_s$-

-$(CH_2)_r$NR'"$(CH_2)_s$NR""$(CH_2)_t$-

wherein -R'" and -R"" are radicals, same or different, selected from the group consisting of H and (C_1-C_3)-alkyl; r is an integer from 1 to 3; s is an integer from 1 to 3; t is an integer from 1 to 3; and

-G_2 is a radical selected from a radical of formula (II), the N-radical of 1,8-naphthalimide, the C4-radical of 2-phenylquinoline, and the C9-radical of acridine.

21. (Currently Amended): A pharmaceutical composition comprising a therapeutically effective amount of the compound as defined in claim 1, together with appropriate amounts of pharmaceutical excipients or carriers.

22. (Previously Presented): A method of manufacturing a composition of matter comprising formula (I) and one of the following processes:

Process I:



when biradical -B- in -G_1 is -CONH- and -G_2 is not an N-radical of 1,8-naphtalimide; and

wherein GP represents an amino protective group and wherein formula (IV) is a monoprotected bis-amine; or

Process II:



when biradical -B- in -G_1 is -CONH- and -G_2 is 1,8-naphtalimide; and

wherein GP represents an amino protective group and wherein formula (IV) is a monoprotected bis-amine; or

Process III:



when biradical -B- is a biradical selected from a group of: $-NR_{13}-$, -O-, $-(CH_2)_nNH$, and $-(CH_2)_nO-$; and

wherein GP represents an amino protective group.